An assessment of dyssynchrony is usually undertaken prior to CRT in order to identify patients who are likely to improve – and avoid implanting a pacemaker in those unlikely to benefit.

Pacemakers and cardiac resynchronization therapy pacemakers are small, battery-powered devices that are surgically implanted ...

Methods: We exposed 12 ICDs and eight CRT-ICDs to 400 cGy of scatter radiation ... 5 Gy Vitals done before and after each treatment with pacemaker-dependent ECG with first treatment Cardiologist ...

EBR designed its WiSE system to significantly expand the population of patients who could benefit from CRT. The leadless ...

Surge in geriatric population along with rise in prevalence of cardiovascular diseases (CVDs), increase in technological advancements in the CRT pacemakers and CRT defibrillators, and rise in ...

The US FDA has approved EBR System's leadless pacemaker WISE, the only heart device able to deliver left-ventricle stimulation.

Tech Innovation Reframes Cardiac Care Strategy A new wave of technological innovation is revolutionizing the biventricular pacemakers market. From AI-powered diagnostic tools to Bluetooth-enabled real ...

EBR Systems, Inc. (ASX: EBR) has received FDA approval of the WiSE® System, which marks a significant leap forward in the treatment of heart failure. Unlike conventional CRT, the WiSE System is the ...

Patients with high procedural risk for LV lead placement Patients with leadless pacemakers* who need CRT, yet are often poor candidates for conventional upgrades In short: WiSE brings CRT to more ...